









%NK (median) 45 13.3% 17.2% p¼0.035
80 7.0% 11.3% p¼0.0015
%NK/PD-1
(median)
45 0.59% 0.42% ns
80 0.96% 0.37% p¼0.0003
%NK/IFN-g
(median)
45 2.7% 1.2% p¼0.03
80 1.8% 1.2% p¼0.03
%NK Perforin
(median)
45 60.2% 39.2% p¼0.04
80 25.4% 41.8% ns
%NK/Granzyme
(median)
45 91.3% 85.7% p¼0.02
80 89.8% 86.2% p¼0.04
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S145found that their post-transplant immune recovery was
characterized by a failure to recover early thymopoiesis and
impairment of functional T cell recovery, compared to other
recipients of autologous or allogeneic transplants (Koman-
duri et al., Blood, 2007). We now report a more extensive
study of adult CBT recipients in whom thymopoiesis was
prospectively assessed by measuring T cell receptor excision
circles (TRECs) in the peripheral blood. Thymic function was
assessed prior to CBT, and at varying intervals thereafter. A
total of 71 adult CBT recipients were assessed prior to CBT
and also assessed at least once within the ﬁrst 180 days after
CBT. Of these recipients, 44 of 71 had detectable thymopoi-
esis prior to the start of conditioning (62%), while baseline
thymopoiesis was undetectable in others (38%). In CBT re-
cipients with detectable thymopoiesis at baseline, 32% had at
least one sample demonstrating detectable thymopoiesis by
six months post-transplant. In contrast, only 4% of subjects
with a negative baseline had any detectable thymopoiesis by
six months. These results suggest that the recovery of early
thymopoiesis within the ﬁrst six months of CBT in adults
may be dependent on functional thymopoiesis at baseline.
Univariate landmark of a subset of these CBT recipients
(n¼41) stratiﬁed by the recovery of thymopoiesis at six
months after CBT demonstrated that recovery of thymopoi-
esis was positively associated with overall survival (HR¼0.2,
95% conﬁdence interval 0.1-0.7, P¼0.01), and also with
decreased non-relapsed mortality (HR¼0.2, 95% conﬁdence
interval 0.1-0.9, p¼0.04). Larger studies of baseline thymo-
poiesis prior to hematopoietic transplantationwill be helpful
to conﬁrm these ﬁndings and ascertain how and why thy-
mopoiesis is preserved in a subset of patients, and to deter-
mine more precisely the relationship of baseline function
and post-CBT outcomes.
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Cytomegalovirus (CMV) infection represents a major
complication in hematopoietic stem cell transplantation
(HCT). There is accumulating evidence that immune re-
sponses to CMV infection involve the expansion of speciﬁc
subsets of NK cells largely driven by the activating receptor
NKG2C.
Under an IRB approved protocol (COH 09038), we prospec-
tively examined the reconstitution of NK cells post-HCT
(days 21, 30, 45, 80 and 120) with regards to their immu-
nophenotypes and functions. A total of 111 patients are
enrolled (median age: 54, range 19-70) who underwent HCT
from related (n¼49) or unrelated donors (n¼62) after either
fully ablative (n¼36) or reduced-intensity (n¼75) condi-
tioning. Donor (D)/Recipient (R) serostatus was D+/R+ in 69,D-/R+ in 33, and D+/R- in 6 pairs. Acute GVHD grade II-IV was
observed in 49 patients (47%). CMV reactivations were seen
in 26 patients (23.4%) with the median time of reactivation
on day 49, including 2 cases of CMV disease.
CMV reactivationwas signiﬁcantly associated with increased
%NK cells expressing PD-1, IFN-gamma, perforin, and gran-
zyme B (Table 1). More focused analysis on available day 80
samples (n¼75) demonstrated a signiﬁcant increase in NK
cells expressing NKG2C in patients with CMV reactivations
(24.2%, n¼17) compared with no reactivations (13.2%, n¼58,
p¼0.018), consistent with published reports. Among
NKG2C+NKcells, CMV reactivation was associated with
increased granzyme B (85.4% vs. 56.9%, p¼0.003) and Ki67
expression (7.0% vs. 2.9%, p¼0.03).
We further explored NK responses to CMV antigen by co-
culturing PBMC (day 80 samples) and pp65 peptide mix for
24 hours. There was no signiﬁcant change in %NKG2C+NK
cells before and after pp65 stimulation. Interestingly,
NKG2C-NK cells showed a response to pp65 stimulation in
their expression of CD137 (pre: 0.06% vs. post: 0.23%,
p¼0.005) and IFN-gamma (pre: 1.6% vs. post: 2.1%, p¼0.03 in
CMV reactivators), suggesting a potential role of NKG2C-NK
cells in CMV infections.
In summary, our data support that CMV reactivation is
associated with expansion (Ki67) and cytotoxic functions
(perforin, granzyme, IFN-gamma) of NK cells expressing
NKG2C following allogeneic HCT.201
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Poor reconstitution of T cell immunity after umbilical cord
blood transplantation (UCBT) results in susceptibility to viral
infections that require intact T cell immunity. Epstein Barr
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S146virus (EBV) is a gammaherpes virus that is reactivated from
latent to lytic cycle and can cause aggressive lymphomas
known as post transplant lymphoproliferative disorder
(PTLD) in immunocompromised hosts. We attempted to
distinguish immune reconstitution proﬁles in double UCBT
recipients who developed EBV viremia from those who did
not. Thirty-one patients with hematologic malignancies
received dUCBT with melphalan, ﬂudarabine, ATG condi-
tioning and tacrolimus plus sirolimus for GvHD prophylaxis.
During the ﬁrst 12 months after dUCBT, 14 of 31 (45%) pa-
tients developed EBV viremia and four (13%) developed
PTLD. At one month after dUCBT, patients with EBV viremia
displayed higher numbers of CD19+ B cells (p¼0.04) and
CD4+CD25+ Treg cells (p¼0.03) compared with patients
who never became viremic. Surprisingly, EBV viremia
correlated with increased numbers of CD3+ (p¼0.04), CD4+
(p¼0.015) and CD8+ (p¼0.021) T cells, but this response was
ineffective at controlling the virus. One explanation for this
unexpected result might be skewing towards a late effector
memory T cell phenotype, a stage in which T cells are inca-
pable of mounting protective immune responses. We
examined naïve vs. memory T cell distribution and deter-
mined that patients who developed EBV reactivation had
higher numbers of memory cell subsets (CD4+CD45RO+,
p¼0.023; CD8+CD45RO+, p¼0.019) at two months after
dUCBT. Analysis of repertoire diversity by deep-sequencing
on PCR-ampliﬁed CDR3 regions of the TCRb gene using the
ImmunoSEQ assay showed a more diverse TCR repertoire, as
determined by higher entropy (p¼0.03) and lower clonality
(p¼0.03), among patients who did not develop EBV reac-
tivation. Assessment of SCF and IL-7, critical regulators of
hematopoietic stem cell and naïve T cell homeostasis,
respectively, showed that patients without EBV viremia had
higher levels of SCF (p¼0.0016) and IL-7 (p¼0.046)
compared with patients who developed viremia and PTLD.
Our ﬁndings suggest that control of EBV reactivation after
dUCBT might be linked to the support of naïve T cell ho-
meostasis, which enables maintenance of a diverse TCR
repertoire.202
Effect of Mobilization Method on Immune Reconstitution
Post High Dose Chemotherapy and Autologous Stem Cell
Transplantation
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for Cellular Therapy, Orlando, FLIntroduction: Plerixafor is a reversible CXCR4 antagonist
that has been approved by the food and drug administration
for autologous hematopoietic stem cell mobilization in pa-
tients withmultiplemyeloma and non-hodgkin’s lymphoma.
Patients mobilized with Plerixafor were shown to have a
higher proportion of primitive stem cells (CD34+/CD133+/
CD38-), CD4+ T cells and Natural killer cells (CD3-/CD16+/
CD56+) in the graft composition when compared to patients
mobilized with chemotherapy plus G-CSF alone. We inves-
tigated the effect of Plerixafor on immune reconstitution
at thirty and sixty days post autologous stem cell
transplantation.
Methods: Patients eligible for autologous stem cell trans-
plantation were enrolled on a single arm prospective im-
mune reconstitution trial. A complete blood count,
differential and lymphocyte ﬂow cytometry panel (T cell, NK
cell and B cell markers) was checked on Days 30 and 60 post
autologous transplantation. Stem cell mobilization was car-
ried per our institutional standards. All patients received
subcutaneous G-CSF at a dose of 10 mg per kilogram body
weight for four consecutive days. On Day4, patient with a
peripheral CD34 count of 20/ml received plerixafor 0.24mg/
kg. Collection was started on day 5 and continued till
collection goal was reached or patient failed to get the
minimal cell dose after 4 consecutive days of pheresis.
Results: 49 patients were enrolled during the period from
September 2010 till May 2012. Median age at time of
transplantation was 54 years (range 21;72 years). 35 pa-
tients had multiple myeloma and 14 had non-Hodgkin’s
lymphoma. 16 patients received GCSF alone (group A) and
33 had plerixafor plus GCSF (group B) for mobilization. All
patients achieved the minimum target of CD34 collection.
The mean number of collection days was 1.9 and 1.4 days
(p¼0.05) with a total collection dose of 7.76 and 7.61 CD34
x106/Kg for groups A and B respectively. The percentage
proportion of CD34 in the aphaeresis product was 0.73%
and 0.75% (p¼0.9) for group A and B. Total infused CD34
dose was similar in both groups (4.88 and 4.56 CD34x106/
kg) with time to engraftment of 11.68 vs 11.69 days for
neutrophils and 20.62 vs 21.39 for platelets in groups A and
B respectively. There was no difference between day 30
absolute lymphocyte count (1.09 vs 1.44 x103/mm3
p¼0.18); Absolute NK cell (0.31 vs 0.35 x103/ml; p¼0.51);
absolute T cell count (0.71 vs 0.96 x103/ml p¼0.33) and
absolute neutrophil count (2.98 vs 2.63 x103/mm3 p¼0.37).
The cell count recovery was also not signiﬁcantly different
when analyzed per disease (myeloma or non-Hodgkin’s
lymphoma) and at day 60.
